Letter: Enhancement of fibrinolytic activity.
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D007249:Inflammation / Q000188:drug therapy; D010447:Peptide Hydrolases / Q000494:pharmacology / Q000627:therapeutic use; D010770:Phosphotransferases / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D005343:Fibrinolytic Agents; D010770:Phosphotransferases; D010447:Peptide Hydrolases; D013300:Streptokinase